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Abstract 
Studies suggests that patients with deep vein thrombosis and diabetes often have hyper co-
agulable blood plasma leading to higher chances of forming thromboembolisms by the rupture of 
blood clots, which may lead to stroke and death. Despite the advances in the field of blood clot 
formation and lysis research, the change in mechanical properties and its implication into the for-
mation of thromboembolisms in platelet poor plasma is poorly understood. In this paper, we present 
a new computational method to simulate fibrin clot formation using molecular simulations. With an 
effective combination of reactive molecular dynamics concept and coarse graining principle, we have 
utilized the reactive coarse grain molecular dynamics to predict the complex network formation of 
fibrin clots and the branching of the fibrins. The heavy 340 kDa fibrinogen is converted into a simple 
spring-bead coarse grain system with 9 beads, and using our customized reactive potentials, we sim-
ulated the formation of the fibrin clot. Thus, formed fibrin clot agrees with the experimental results 
qualitatively, and to our best knowledge this is the first kind of molecular polymerization study of 
fibrin clot which can lead to improve our understanding about blood clot formation and its relation-
ship with mechanical properties. 
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Introduction 
Deep vein thrombosis is the formation of a blood 
clot (thrombus) within a deep vein most commonly 
in the legs, which can lead to wide range of compli-
cations[1]. In the event of rupturing of the thrombus, 
it may travel to the lungs and leads to pulmonary 
embolism which can be fatal[2, 3] if left untreated. 
Vascular endothelial damage, stasis of blood flow, 
and hypercoagulability of blood is found to be di-
rectly related to the risk factors of deep vein throm-
bosis[4-7] and pulmonary embolism[8-11]. The ve-
nous thromboembolism is considered as an epi-
demic[12-16] and various thrombolytic therapies 
are suggested by the clinicians to control it after a 
typical surgery[17-27]. The characterization of the 
mechanical properties of the thrombo-emboli plays 
an important role in developing thrombolytic thera-
pies[28], and towards this goal a number of studies 
have been done recently[29-33]. Despite of all these 
developments in this area, the computational mod-
eling is not well developed. An accurate computa-
tional model based on the molecular information 
will be helpful in predicting the mechanical behav-
ior of the blood clots under various pathogenic states 
and also can be helpful to design better thrombolytic 
therapies. In this work, towards this goal we will lay 
the foundations of simulating fibrin clot using mo-
lecular dynamics simulations. 
The fibrinogen is a big soluble glycoprotein 
which plays a major role in the event of blood clot, 
by forming network of fibrins which is the basis of 
a blood clot. It took almost 50 years to get the accu-
rate structural representation of the fibrinogen mol-
ecule[34]. Previously, the tri-nodular structure of 
the fibrinogen molecule was determined by various 
methods including electron micrographs[35]. Using 
the molecular models of fibrinogen and thrombin, 
an enzyme which cleaves the fibrinopeptides of fi-
brinogen and thereby initiating the polymerization, 
studies were conducted to understand their interac-
tions[36]. Towards the simulation of blood clot and 
blood flow, there exists a few studies with discrete 
particles[37] and multiscale models[38-41]. There 
are studies aimed at understanding the adsorption 
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behavior of the fibrinogen with different types of 
surfaces[42] which can be helpful in understanding 
immunological response[43].  
Even after this many computational studies re-
lated to blood clot, there exists no models which can 
accurately predict the formation of the blood clot, its 
mechanical behavior, adsorption, and lysis events 
based on the molecular information. They are 
mainly based on the empirical rate of clot formation 
information modeled as first order differential equa-
tion. A multiscale model which can leverage the mo-
lecular information to the macroscale clot mechani-
cal properties can elucidate the thrombus rupture 
mechanism and thereby we can aim at developing 
new targeted thrombolytic therapies. As the first 
step towards this, we have developed a highly coarse 
grain model of fibrinogen and then this solvent free 
model along with the modified reactive molecular 
dynamics potentials we simulate the clot formation 
at molecular level. The force field parameters are 
optimized using our custom written computer code, 
and we have observed some important events in the 
fibrin clot such as the continuous long strand for-
mation, and fibrin branching and cross-linking. 
Coarse Grain Model Development 
A coarse grain model with minimal number of 
beads is preferred for fibrinogen to avoid the com-
putational overhead, at the same time having enough 
beads and springs to maintain the flexibility and ex-
tensibility of the molecule. With this in mind, we 
used a shape based coarse graining approach and 
have divided the human fibrinogen (RCSB 
3GHG[34]) molecule into nine fragments and esti-
mated their molecular mass and converted them into 
beads separated by harmonic springs of 5.75 nm in 
length. Figure 1a shows the molecular model of hu-
man fibrinogen[34] with α, β, and γ-chains along 
with the D-region, E-region and the coiled region 
(C-region). The mass partitioning procedure is 
shown in Fig. 1b, and the final coarse grain model is 
shown in Fig. 1c with C-type, D-type and E-type 
beads. The type-C beads weigh 20 kDa, type-D 
weighs 32.5 kDa and type-E weighs 25 kDa respec-
tively. Additionally, type-T beads (not shown in fig-
ure) are considered with 20 kDa mass which func-
tions similar to thrombin. The actual molecular 
weights of thrombin (RCSB 1PPB[44]) is 34.3 kDa 
and factor XIII (RCSB 1GGU[45]) is 166 kDa; 
however to enhance the mobility of T-bead in a sol-
vent-free environment, we arbitrarily selected it as 
20 kDa. 
To maintain the connectivity and simulate the 
elastic behavior, we used a harmonic bond potential 
(Eqn. 1) which connects bead-D to bead-C, bead-C 
to bead-C and bead-C to bead-E. 
𝑉𝑏𝑜𝑛𝑑 = 𝑘𝑏(𝑟 − 𝑟0)
2 (1) 
Here, 2𝑘𝑏 is the stiffness of the spring, 𝑟0 is the equi-
librium distance of the bonds, and 𝑟 is the spacing 
between the beads in the bond. The value of the lin-
ear spring stiffness is estimated from all atom mo-
lecular dynamics simulation[46] of a single fibrino-
gen molecule as 0.75 𝑁 𝑚⁄ . The equilibrium bond 
distance is considered as 5.75 𝑛𝑚 between all types 
of beads, which accounts for the actual fibrinogen 
length of 46 nm. For maintaining the shape and to 
avoid worm-like chain behavior of the fibrinogen 
molecule we applied an angle harmonic potential 
(Eq. 2) between every adjacent bond. 
𝑉𝑎𝑛𝑔𝑙𝑒 = 𝑘𝑎(𝜃 − 𝜃0)
2 (2) 
Here, 𝑘𝑎 is the potential stiffness, which controls 
the flexibility of the bonds and 𝜃0is the equilibrium 
angle in this case taken as 180 deg.  
Arbitrarily, we assigned 10.432
𝑘𝐽
𝑚𝑜𝑙 𝑟𝑎𝑑2
 as the 
spring stiffness, which makes the molecule neither 
too stiff nor too flexible. This value can be and has 
to be optimized to reflect the bending stiffness of the 
molecule; nevertheless, this study was aimed at the 
polymerization and hence we chose it arbitrarily. 
All the beads interact with each other using a 
standard shifted truncated LJ potential (Eqn. 3) with 
a cutoff radius of 50 nm. The potential and its nega-
tive derivative (force) goes to zero smoothly when 𝑟 
approaches cutoff radius (𝑟𝑐). The depth of the po-
tential well (𝜀) is 0.23838 𝑘𝐽/𝑚𝑜𝑙 (same as argon) 
and 𝜎 = 4 𝑛𝑚 is used between all beads. However, 
𝜎 is changed to 2.5 𝑛𝑚 between C-C bead interac-
tion, and to 1 𝑛𝑚 between beads T and E.  
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Figure 1: Coarse graining steps of fibrinogen molecule. (a) Molecular model of human fibrinogen with α-chain, β-chain and γ-
chain in cartoon representation using VMD[47]. (b) Partitioning of the fibrinogen molecule based on the mass. (c) Coarse grain 
model of fibrinogen with mass, bond length and type of different beads. 
This is to avoid unnecessary calculation of LJ 
potential and harmonic potential at the same time, 
which may lead to a bouncing off (repulsive LJ) and 
attraction (harmonic). Here bead-T represents the 
thrombin bead, and its role is discussed in the next 
section. 
𝑉𝐿𝐽 = 4𝜀 [(
𝜎
𝑟
)
12
− (
𝜎
𝑟
)
6
] − 4𝜀(𝑟 − 𝑟𝑐) [
6𝜎6
𝑟𝑐7
−
12𝜎12
𝑟𝑐13
] − 4𝜀 [
𝜎12
𝑟𝑐12
−
𝜎6
𝑟𝑐6
] (3) 
The Eqn. 3 represents the shifted LJ potential, where 
𝑟 is the inter atomic/bead spacing. 
Polymerization force field development 
In this section, we will explain the general path-
way of fibrin clot formation, the molecular mecha-
nism behind it, development of the polymerizing 
force field, and the development of the computer 
code used for simulating the fibrin clot. 
Mechanism of Fibrin polymerization 
The fibrinogen is converted to fibrin monomer 
upon the cleaving of fibrinopeptides in the E-region 
by activated thrombin (factor IIa), and remains 
bound to the fibrinogen molecule[48-50]. These fi-
brin monomers will start forming protofibrils of two 
fibrins, which starts polymerizing as long strands. 
These long strands in the presence of factor XIIIa, 
will aggregate laterally and will form a stable fibrin 
clot. The factor XIIIa also binds into fibrin clot[51, 
52] and completes the coagulation cascade[53]. The 
various steps involved in this process is explained 
graphically in Fig. 2 and a detailed description of the 
chain of events and various stages of coagulation 
cascade are in the literature[53, 54]. Figure 2a shows 
the schematic of fibrinogen molecule along with the 
thrombin beads suspended in the plasma system. An 
exact molecular simulation of this bio-chemical re-
action at atomic scale is very challenging to simu-
late, and hence we rely on specially developed sol-
vent free coarse grain force field to demonstrate the 
clotting process. Figure 2b shows the phase-I of the 
polymerization, in which the thrombin cleaves the 
fibrinopeptides of the fibrinogen and makes fibrin 
monomers. In reactive coarse grain molecular simu-
lations (RCGMD), we simulate this by bonding 
type-T beads to type-E beads. In the next phase, the 
fibrin monomers will start polymerizing with each 
other, type-D beads bonding to type-T beads with 
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specific rules, and this similar to the thrombin bind-
ing on D-region[55]. This process is referred to as 
phase-II polymerization. The time evolution of this 
simulation will demonstrate the long fibrin strand 
formation and lateral branching and aggregation of 
the fibrin polymers as shown in Fig. 2c. 
 
Figure 2: A conceptual representation of the fibrin polymerization. (a) Fibrinogen molecules and thrombin like beads. (b) The 
T-beads attaches to E-beads, which is analogous to the process of thrombin (factor IIa) cleaving the fibrinopeptides (fpA and 
fpB). (c) In this stage, D-beads bonds with T-beads, which is analogous to the D-regions bonding to E-region in clotting cascade. 
(d) Molecule code naming conventions for various beads. Note that T-beads (Type 4) is just a mediator to form bonds in simu-
lations, which has similar functions of thrombin. 
The RCGMD basis of the fibrin clotting process 
can be classified into phase-I and phase-II, in which 
the common types of potentials are used along with 
rule based switching functions to enable the clotting 
simulation. 
Phase I: Type 3-4 bonding 
RCGMD force field consists of three poten-
tials, an attractive, a repulsive and a bonding poten-
tial as shown in equations 4, 5 and 6 respectively. 
Here, 𝑘1is the common constant for attractive and 
repulsive potential, 𝑘2 is the spring constant for 
bonding potential, 𝑟𝑏𝑜𝑛𝑑 is the bond distance be-
tween bead types 3 and 4, and 𝑟 is the inter-bead 
distance. 𝑟𝑏𝑜𝑛𝑑 is kept as 3.5 𝑛𝑚 for all our simula-
tions. 
𝑉𝑎𝑡𝑡𝑟𝑎𝑐𝑡 = −𝑘1 (𝑟 − 𝑟𝑏𝑜𝑛𝑑)
2⁄  (4) 
𝑉𝑟𝑒𝑝𝑒𝑙 = 𝑘1 𝑟⁄  (5) 
𝑉𝐵𝑜𝑛𝑑𝑖𝑛𝑔 = 𝑘2(𝑟 − 𝑟𝑏𝑜𝑛𝑑)
2 (6) 
These potentials are combined together using 
heavyside functions as shown in eqn. 7 to get the 
phase-I RCGMD potential. Heavyside function 
(eqn. 13) acts as a switch, which returns a value of 1 
for positive numbers, 0 for negative and 0.5 for zero. 
Unit of 𝑘1 in Eqn. 4 is 𝑘𝐽. 𝑛𝑚
2 𝑚𝑜𝑙⁄  and 
𝑘𝐽. 𝑛𝑚 𝑚𝑜𝑙⁄  in Eqn. 5, and 𝑘2 is 𝑘𝐽 (𝑚𝑜𝑙. 𝑛𝑚
2)⁄ . 
Despite of the unit differences, we chose a common 
constant for repulsive and attractive potential as 𝑘1 
so as to reduce the optimization effort. 
𝑉𝑟𝑐𝑔𝑚𝑑−𝐼 = (Θ1Θ4)𝑉𝑎𝑡𝑡𝑟𝑎𝑐𝑡 + (Θ2Θ5)𝑉𝐵𝑜𝑛𝑑𝑖𝑛𝑔 +
(Θ3 + Θ2Θ4)𝑉𝑟𝑒𝑝𝑒𝑙 (7) 
Θ1 = Θ(0.9 − 𝑁34) (8) 
Θ2 = Θ([𝑁34 − 0.9] [1.1 − 𝑁34]⁄ ) (9) 
Θ3 = Θ(𝑁34 − 1.9) (10) 
Θ4 = Θ(𝑟
2 − 𝑟𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑
2 ) (11) 
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Θ5 = Θ(𝑟𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑
2 − 𝑟2) (12) 
Θ(𝑡) = {
0, 𝑓𝑜𝑟 𝑡 < 0 
1 2⁄ , 𝑓𝑜𝑟 𝑡 = 0
1, 𝑓𝑜𝑟  𝑡 > 0
 (13) 
 
Figure 3: Different types of potentials that we used to develop the reactive force field. (a) It consists of a shifted attractive 
potential, a repulsive potential and a harmonic potential. (b) when no type-4 beads are inside the threshold region, all the type-4 
beads within the cutoff radius will experience an attractive force from type-3 beads. (c) when only one type-4 bead is inside 
threshold region, then it begins to experience bonding force with type-3 bead. (d) At this stage type-4 bead forms a strong 
harmonic bond with type-3 bead and this completes the phase I. The total force between type-4 bead and the type-3 bead during 
these stages are shown in (e), (f) and (g). Note that the force is zero in threshold region (e) as there is no qualifying beads in that 
region. 
Equations 8 to 12 represents the heavyside func-
tions used in the phase-I RCGMD potential, where 
𝑁34 is the number of type 4 beads around a type 3 
bead, 𝑟𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 is the threshold distance at which we 
turn on the bonding potential, and 𝑟 is the inter-bead 
distance. The working principle of RCGMD phase-
I potential is shown graphically in Fig. 3. Figure 3a 
shows the force versus inter-bead spacing for attrac-
tive, repulsive and bonding potentials. Figure 3b-d 
shows three cases or stages at which the bonding be-
tween type 3 and 4 happens. At stage 1 as in Fig. 3b, 
when all the type 4 beads are outside the threshold 
region of a type 3 bead, then they all experience an 
attractive force as shown in Fig. 3e.  
When one type 4 bead enters into the threshold 
region, the bonding potential is turned on inside the 
threshold region and the repulsive potential is turned 
on outside it as shown in Fig. 3f. This will allow one 
of the type 4 bead to get bonded with type 3 bead, 
and other type 4 beads move away from this zone 
and are no longer attracted to the type 3 as seen in 
Fig. 3c. This process will lead to a strong bond for-
mation between one of the type 4 and type 3 bead as 
shown in Fig. 3d. Again, the potential remains the 
same as shown in Fig. 3g. In a highly dynamic envi-
ronment if multiple type 4 beads enter into the 
threshold region, then the bonding potential is 
turned off and all the type 4 beads are repelled by 
the type 3 bead. This rule will prevent unnecessary 
clustering of T-beads onto the E-region.  
In a typical scenario, all type 3 beads should 
have a made a bond with a type 4 bead in a short 
period of time, to simulate the polymerization be-
havior of fibrin. The phase-II potentials are designed 
to work with fibrins which already have made type 
3-4 bonds. 
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Phase II: Type 2-4 bonding 
In this phase of RCGMD, potentials for the 
polymerization of fibrin monomers is developed. 
The attractive, repulsive and the bonding potentials 
(Eqn. 14) are the same from phase-I, except the 
switching functions are modified this time (Eqns. 
15-20). Additionally, Θ6 is introduced, which will 
switch on the phase-II, only if phase-I is complete. 
𝑁𝑋𝑌 represents the number of type 𝑌 beads around 
type 𝑋 beads, and the other terms remains as the 
same as in phase-I. 
𝑉𝑟𝑐𝑔𝑚𝑑−𝐼𝐼 = Θ6{(Θ1Θ4)𝑉𝑎𝑡𝑡𝑟𝑎𝑐𝑡 +
(Θ2Θ5)𝑉𝐵𝑜𝑛𝑑𝑖𝑛𝑔 + (Θ3 + Θ2Θ4)𝑉𝑟𝑒𝑝𝑒𝑙} (14) 
Θ1 = Θ(0.9 − 𝑁42)Θ(0.9 − 𝑁24) (15) 
Θ2 = {Θ (
𝑁42−0.9
1.1−𝑁42
) + Θ (
𝑁42−1.9
2.1−𝑁42
)} Θ (
𝑁24−0.9
1.1−𝑁24
) (16) 
Θ3 = max(Θ(𝑁24 − 1.9), Θ(𝑁42 − 2.9)) (17) 
Θ4 = Θ(𝑟
2 − 𝑟𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑
2 ) (18) 
Θ5 = Θ(𝑟𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑
2 − 𝑟2) (19) 
Θ6 = Θ (
𝑁43−0.9
1.1−𝑁43
) (20) 
This potential will make sure that a bond is formed 
between type 2 and 4 beads, only if there is a maxi-
mum of two type 2 beads around type 4 bead, and 
maximum of one type 3 bead around type 4 bead. 
This will prevent clustering of the fibrins at a partic-
ular location. 
Computer code development 
The RCGMD potentials are implemented and 
tested in a custom written parallel Python code. 
Then it was converted to a faster C++ version with 
which we did all the simulations in this study. The 
codes consist of implementation of standard poten-
tials like Lennard Jones, harmonic bond potential 
and harmonic angle potential. The numerical inte-
gration is performed using velocity Verlet 
scheme[56], and the temperature of the system is 
controlled using velocity scaling thermostat. To ac-
count for large scale simulations, the code can read 
input from a file and data file which closely resem-
bles that of LAMMPS[57], so that in the future the 
code can be easily migrated to LAMMPS[57]. 
 
Figure 4: (a) A 200 𝑛𝑚3 equilibrated molecular model with 120 fibrinogens and 150 type-4 beads is used for the simulations. 
The different types of beads are labeled in the subfigure. Parameter estimation and sensitivity check for 𝑘1 and 𝑘2 (equations 4-
6) against the rate of phase-I and phase-II bonding. The figure shows number of bonds formed per ns versus (b) 𝑘1 and (c) 𝑘2. 
The total number of bonds formed after 100 ns of simulation is estimated while changing the (d) 𝑘1 and (e) 𝑘2.  
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Results and Discussion 
After the development of the RCGMD potential, 
the next steps were to test it to check the bonding 
rate, time step of integration and its influence on 
bonding rate and stability, parametric optimization 
of the potential constants etc. In this section, we will 
describe the simulation model that we used for the 
preliminary studies, optimization of the force field 
parameters, estimation of an optimum time step of 
integration and some large system fibrin polymeri-
zation studies. 
Simulation model 
A cubic periodic system with sides 200 𝑛𝑚 with 
120 fibrinogens and 150 type 4 beads is chosen as 
the molecular model for preliminary studies. This 
system is equilibrated for 50000 steps with a time 
step of 200 𝑓𝑠 before using it for any production 
runs. The equilibrated system is as shown in the Fig. 
4a along with various types of beads marked on it. 
During this equilibration process, the RCGMD po-
tentials are turned off and no bond formation is al-
lowed with type 4 beads. The density of the fibrino-
gen molecules in this equilibrated system represents 
the physiological concentration of human fibrino-
gen[58] which is in the range of 3 𝑡𝑜 4.5 𝑔 𝐿⁄ . The 
physiological concentration of thrombin[59] is too 
low which makes an equivalent of three or four type 
4 beads in this system. This will lead to poor 
polymerization, as our RCGMD is based on the cen-
tral bead as type 4. Hence, we cannot directly com-
pare thrombin with type 4, instead we should have 
equal number of type 4 corresponding to type 3 
beads in RCGMD. To avoid the clustering of the 
type 4 beads into a sphere, we turned off any type of 
interaction among type 4 beads. 
Parameter influence on polymerization rate 
To start with, the equilibration studies are per-
formed with arbitrary values of 𝑘1 = 100 and  𝑘2 =
15. Our next step is to justify this selection and also 
the check the sensitivity of type 3-4 and 2-4 bond 
formation rate with respect to 𝑘1 and  𝑘2.Using the 
equilibrated model, we have performed simulation 
for 100 𝑛𝑠 with a time step of 200 𝑓𝑠. In the first 
set of simulations the 𝑘2 = 15, and the 𝑘1 is varied 
from 0 to 500. In the second set of simulations, 𝑘1 =
100 and 𝑘2 is varied from 0 to 100. The initial rate 
of bonding of type 3-4 and type 2-4 is estimated for 
both cases and plotted in Fig. 4b and 4c. The results 
show a linear correlation between the rate of bond 
formation and 𝑘1. This trend is expected, since the 
increase in 𝑘1 will increase the force of attraction 
leading to faster movement of type 4 beads towards 
type 3 beads, and hence bonds faster. On the other 
hand, second set of simulations show that increasing 
𝑘2 will actually decrease the chances of bonding. A 
range in between 0 and 20 is preferred for 𝑘2, for a 
stable bonding as shown in Fig. 4c. This is due to 
the nature of the harmonic bond; as 𝑘2 represents the 
spring constant of bonding potential, larger values 
of 𝑘2 can lead to “bouncing off” of the type 4 bead 
with type 3 in conjunction with the time step of in-
tegration. 
 
Figure 5: For the 200 𝑛𝑚3 fibrinogen system, the rate of bonding is estimated by changing the parameters. (a) The variation of 
phase-I bonding (type-4 to type-3) with 𝑘1 and 𝑘2 is shown with contours representing the number of bonds per ns. (b) The 
variation of phase-II bonding (type-4 to type-2) with 𝑘1 and 𝑘2 is shown with contours representing the number of bonds per ns. 
(c) The total number of phase-I bonds formed over 100 ns while varying 𝑘1 and 𝑘2 is shown with contours representing the total 
number of bonds after 100 ns. 
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Figure 6: Estimation of optimal time step of integration. (a) Evolution of average total energy of the system with various time 
step of integration. (b) Change of system temperature with respect to time step. 
 
The initial rate of bond formation doesn’t give 
any information on the stability of the bonds formed. 
Hence, additionally, we have estimated the total 
number bonds formed after 100 𝑛𝑠 simulation. The 
results are shown in Fig. 4d and 4e for both 𝑘1 and 
𝑘2 variations, and it shows that the 𝑘1 doesn’t influ-
ence much after a value of 100, but 𝑘2 keeps the 
same trend as in Fig. 4c. So in practice, we can select 
𝑘1 around 100 and 𝑘2 around 10. All simulations are 
repeated 5 times (155 in total) to reduce the statisti-
cal fluctuation and the error bars in the Fig. 4 indi-
cate the standard deviations. After this preliminary 
study, we down selected the parameter ranges of 𝑘1 
and 𝑘2 from 0 to 200 and from 0 to 50 respectively 
and did a two-dimensional parametric sweep to map 
the influence of bonding rates. The results of the 2-
dimensional mapping of parameters versus bonding 
rate and total bond formation is shown in Fig. 5. Fig-
ure 5a and 5b shows the influence of 𝑘1 and 𝑘2 in 
type 3-4 bonding and type 2-4 bonding rates respec-
tively. Apart from this transient bonding rate data, 
we estimated the influence of 𝑘1 and 𝑘2 on the total 
number of type 3-4 bonds formed after 100 𝑛𝑠 and 
shown in Fig. 5c. The red region shows the highest 
number of bond formation, with a decreasing num-
ber towards the blue region (color online). This 
shows that a range of 25 to 200 for 𝑘1 and 1 to 15 
for 𝑘2 is suitable for simulating the polymerization. 
 
Figure 7: Molecular model of 150 fibrinogens and 150 type-4 
beads in a 200 𝑛𝑚3 periodic box. The figure shows the system 
just before equilibration. The fibrinogens and type-4 beads are 
inserted randomly into the box using our algorithm and the dif-
ferent panels show the (a) front view, (b) side view, (c) top 
view and (d) isometric view of the system. 
Time step of integration 
Apart from the parameters’ influence, there ex-
ists other characteristics of the polymerization to ex-
plore for RCGMD simulations. One of them is the 
proper choice of time step of integration. Based on 
the results from the parametric studies, we have se-
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lected 𝑘1 = 100 and 𝑘2 = 10 and kept them con-
stant for all RCGMD simulations going forward. 
For time step studies a denser system is preferred, as 
it can simulate fast collisions between the beads. A 
system with 150 fibrinogens and 250 type 4 beads 
in a 120 𝑛𝑚3 cubic periodic box (not shown in fig-
ures) is chosen to study time step influence on en-
ergy and temperature. First, the system is equili-
brated for 10 𝑛𝑠 at constant temperature of 310 𝐾 
using velocity scaling thermostat with an arbitrary 
time step of 200 𝑓𝑠. Then the thermostat is turned 
off and the time step is changed to a value ranging 
from 1 𝑓𝑠 to 1400 𝑓𝑠. The total energy and temper-
ature of the system is averaged for another 10 𝑝𝑠. 
These values are plotted in Fig. 6a and 6b respec-
tively. The trend shows that the average energy and 
temperature starts diverging when the time step 
value is around 200 𝑓𝑠. So an ideal choice of the 
time step will be 200 𝑓𝑠 or less. Going forward, our 
RCGMD simulations will use the time step as 
200 𝑓𝑠. 
Polymerization studies 
A bigger system of 200 𝑛𝑚3 periodic box with 
150 fibrinogens and 150 type 4 beads as shown in 
Fig. 7 is created to study the fibrin polymerization 
over long periods of time. The type 4 beads and the 
fibrinogens are filled inside the simulation box us-
ing our random molecular filling algorithm, written 
in MATLAB[60]. Figure 7 shows images of this 
molecular model from different angles namely front 
view (Fig. 7a), side view (Fig. 7b), top view (Fig. 
7c) and isometric view (Fig. 7d). The system is 
equilibrated for 50000 steps at NVT ensemble be-
fore doing any polymerization studies. The time step 
of integration is chosen as 100 𝑓𝑠, and the force 
field parameters are chosen as 𝑘1 = 100 and 𝑘2 =
10. The molecular dynamics simulation is per-
formed for 2 𝜇𝑠 (20 million steps) to understand the 
molecular level polymerization details of the above-
mentioned fibrin system. Figure 8a-d shows the time 
elapsed screenshots of the fibrin polymerization us-
ing our RCGMD code. 
.
 
Figure 8: Long simulations of the fibrin system. The molecular model shown in Fig. 7 is equilibrated and run for 2s with a 
time step of 100 fs. The resulting configuration is shown after (a) 17 ns, (b) 357 ns, (c) 1.2 s and (d) 2 s. (e) Continuous long 
fibrin strand formations are observed and a portion of it is marked in red. (f) Fibrin polymers started branching into two strands 
and is marked in red. (g) The perspective view gives a close-up view into the type4-type3-type2 interactions. 
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The screenshots at 17 ns (Fig. 8a), 357 ns (Fig. 
8b), 1.2 s (Fig. 8c) and 2 s (Fig. 8d) show a grad-
ual evolution of the fibrin polymers forming as short 
strands in the beginning, and then growing into long 
continuous networks. A portion of the long strands 
formed is highlighted in the Fig. 8e. After visually 
analyzing the domain with OVITO[61] software, we 
found that there is no single fibrin isolated or inde-
pendent strands after 2 s. The fibers have grown to 
long continuous chains and have interconnected 
with each other as a complex network. This is con-
sistent with the experimental observations related to 
the fibrin scanning electron microscopic (SEM) 
studies[62]. Another important observation is the 
branching and cross-linking of the fibrin polymers 
as seen in Fig. 8f, which shows that all the branches 
tend to have a maximum of two branches at these 
intersections and is in qualitative agreement with the 
experimental results[62, 63]. A detailed view of the 
bonded atoms of the fibrinogen and type 4 beads is 
shown in Fig. 8g 
For all the studies in this work, visualization of 
the molecular models is done using OVITO soft-
ware[61] and molecular models are created using 
MATLAB[60] codes. The images shown in Fig. 8a-
d is created by placing periodic images of the system 
along two directions, and hence they actually repre-
sent six replicas of the molecular system shown in 
Fig. 7. 
Scope for future improvements 
This section discusses some of the possible fu-
ture improvements to be made in the RGMD model. 
(i) Quantitative validation with experimental re-
sults: A quantitative validation can be done if we can 
compare the number density of the fiber junctions, 
thickness of the fibrin fibers, and mechanical 
strength of the clot. For this we need mathematical 
methods[64] to characterize the 3d images of fibrin 
clot network and then quantifying them to compare 
with the simulation results. This is a complex task 
of integrating image processing of confocal imag-
ing, nodule (junctions of fibrin interconnections) de-
tection algorithms, fibrin thickness assessment algo-
rithm and fibrin density estimation algorithm. 
(ii) Mechanical properties: Currently, we have used 
the spring constant as the elastic properties of the fi-
brinogen obtained directly from the atomic simula-
tions[39]. However, the elastic properties of the fi-
nal stable fibrin clot are not estimated and compared 
with the experimental studies. This needs additional 
simulations with stable and equilibrated fibrin clot 
system in conjunction with steer molecular dynam-
ics[65] simulations. 
(iii) Energy conservation: The switching of the 
RCGMD potentials around the threshold region is 
drastic and this may lead to poor energy conserva-
tion with the RCGMD turned on. This issue can be 
addressed by testing the polymerization logic with a 
series of different potentials along with smooth 
switching functions which can smoothly change the 
energy near the threshold radius. 
(iv) Viscosity and fluidic properties: To extend this 
model to integrate with other protein models of hu-
man erythrocytes and blood plasma, we need to val-
idate the viscosity and other fluidic properties of the 
fibrin system before and after clotting. This requires 
investigation of the system with additional particles 
resembling to the highly coarse-grained models of 
water, characterization of the potential parameters 
with cutoff radius etc. 
(v) Multithreaded RCGMD code: To perform a 2 s 
simulation using the current computer code written 
in C++ takes around 96 hours in our cluster compu-
ting as it is serial code. This can be reduced signifi-
cantly by multithreading the LJ force calculation 
module and also utilizing faster alternate potentials 
for RCGMD, which can circumvent the need for 
square root calculation of the inter-bead distance. 
We are working on the most of these challenges 
and will be addressed in the upcoming publication 
series. 
Conclusion 
We have developed a reactive coarse grain mo-
lecular dynamics method to simulate the clotting 
mechanism of human fibrinogen. We started by de-
veloping the highly coarse-grained model of fibrin-
ogen with only 9 beads interconnected through 
springs, which reflect the mechanical properties and 
size of the actual fibrinogen. This coarse grain 
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model is used along with thrombin like coarse grain 
beads to develop our reactive coarse grain molecular 
dynamics (RCGMD) method. The force field pa-
rameters of this new method are characterized 
against the rate of polymerization and mapped into 
a two-dimensional space to understand the extent of 
their influence. Subsequently, we estimated the di-
vergence of average total energy and temperature 
with different time steps of integration and found 
that 200 𝑓𝑠 is the best choice. Then we extended our 
polymerization studies with a bigger system of 150 
fibrinogens and 150 type 4 beads in a 200 𝑛𝑚3 box. 
These simulations predicted the time evolution of 
the fibrin clot formation for over 2 s, and we have 
observed many real phenomena that was seen in fi-
brin clots. One of them is the branching of the fibrin 
fibers into interconnecting networks, another is the 
stable long continuous fibrin strand formation which 
are very consistent with the experimental observa-
tion. This is the first successful attempt on polymer-
ization of the fibrin clot using molecular simula-
tions, and we have qualitatively predicted very sim-
ilar fibrin network formation observed in reality. We 
believe this work will be the foundation of the new 
class of molecular simulations called reactive coarse 
grain molecular dynamics, and our RCGMD con-
cept can be optimized or tuned to accommodate any 
type of bio-chemical reactions at mesoscale. 
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